In a different study, Mes et al. suggested a method for risk stratification that divided laryngeal cancer patients into low-, intermediate-, and high-risk groups based on a panel of genetic changes (TP53, CDKN2A, and CCND1), clinical variables, and HPV status [18]. This evidence concerns the gene CDKN2A and laryngeal carcinoma.